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Purpose: In this study, we investigated the stroke mechanism and the factors associ-
ated with ischemic stroke in patients with nonvalvular atrial fibrillation (NVAF) who 
were on optimal oral anticoagulation with warfarin. Materials and Methods: This 
was a multicenter case-control study. The cases were consecutive patients with 
NVAF who developed cerebral infarction or transient ischemic attack (TIA) while 
on warfarin therapy with an international normalized ratio (INR) ≥2 between Janu-
ary 2007 and December 2011. The controls were patients with NVAF without isch-
emic stroke who were on warfarin therapy for more than 1 year with a mean INR ≥2 
during the same time period. We also determined etiologic mechanisms of stroke in 
cases. Results: Among 3569 consecutive patients with cerebral infarction or TIA 
who had NVAF, 55 (1.5%) patients had INR ≥2 at admission. The most common 
stroke mechanism was cardioembolism (76.0%). Multivariate analysis demonstrated 
that smoking and history of previous ischemic stroke were independently associated 
with cases. High CHADS2 score (≥3) or CHA2DS2-VASc score (≥5), in particular, 
with previous ischemic stroke along with ≥1 point of other components of CHADS2 
score or ≥3 points of other components of CHA2DS2-VASc score was a significant 
predictor for development of ischemic stroke. Conclusion: NVAF patients with high 
CHADS2/CHA2DS2-VASc scores and a previous ischemic stroke or smoking history 
are at high risk of stroke despite optimal warfarin treatment. Some other measures to 
reduce the risk of stroke would be necessary in those specific groups of patients.
Key Words:   Cardiac embolism, cerebral infarction, risk factors, atrial fibrillation, 
anticoagulation
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the department of neurology or cardiology at each study 
hospital during the same time period. We reviewed the 
medical records and results of laboratory tests. Patients 
were included as controls when they had NVAF and re-
ceived warfarin for more than 1 year with a mean INR ≥2. 
Controls should not have a cerebral infarction or TIA for 
one year while they had been on warfarin therapy with their 
mean INR ≥2. Controls were matched 1:1 to cases on age 
and gender. 
Clinical variables
We collected data for demographics, vascular risk factors, un-
derlying cardiovascular diseases, and concurrent medications 
in cases and controls. Atrial fibrillation (AF) was categorized 
as paroxysmal or persistent/permanent AF. The CHADS2 
score or CHA2DS2-VASc scores were calculated for all pa-
tients. The index cerebral infarction or TIA was not consid-
ered for calculating the CHADS2 score or CHA2DS2-VASc 
score. Concomitant potential cardiac sources of embolism 
was defined as having at least one of left atrial/atrial ap-
pendage thrombus, sick sinus syndrome, recent myocardial 
infarction (<4 weeks), left ventricular thrombus, dilated car-
diomyopathy, and akinetic left ventricular segment, along 
with NVAF. Patients were regarded as smokers if they 
smoked within the 3 months period prior to admission. INR 
data were also collected; the INR at admission for cases and 
the mean INR during the 1 year prior to enrollment for con-
trols were used in the analysis. We also calculated time in 
therapeutic range by the method of Rosendaal, et al.11 among 
the patients enrolled as controls (mean number of checking 
INR=6). However, we could not calculate time in therapeutic 
range in cases because all patients included in the case group 
had not followed up before index stroke at each hospital.
We collected data of location of ischemic lesions and the 
initial stroke severity assessed by the National Institute of 
Health Stroke Scale in cases. In patients with cerebral infarc-
tion, we determined the stroke mechanism, which was based 
on the Trial of Org 10172 in Acute Stroke Treatment classifi-
cation.12 Two neurologists (YDK and HSN) independently 
reviewed brain imaging including the diffusion weighted im-
ages and angiographic studies. If the classification was con-
flicting, consensus was reached through the discussion to-
gether with the third investigator (KYL).
Statistical analyses
Statistical analysis was performed using the Windows SPSS 
package (version 18.0, SPSS Inc., Chicago, IL, USA) and 
INTRODUCTION
Nonvalvular atrial fibrillation (NVAF) is the most common 
cause of cardioembolic stroke.1,2 Warfarin (vitamin K an-
tagonist) treatment with optimum intensity has been a stan-
dard treatment to prevent ischemic stroke or systemic em-
bolism in patients with NVAF.3-5
However, despite having a therapeutic intensity of oral an-
ticoagulation (OAC) therapy, some patients still suffer from 
ischemic stroke.6 Some patients may have a hypercoagula-
ble state, and subsequently intractable to appropriate OAC 
therapy.7,8 Furthermore, noncardioembolic stroke such as 
atherothrombotic stroke or lacunar infarction can occur in 
patients with NVAF,9,10 and these types of ischemic stroke 
may not be successfully prevented with OAC. Until now, 
however, there has been limited information regarding the 
clinical determinants for development of ischemic stroke 
and the stroke mechanism in patients with NVAF who were 
on warfarin therapy in real clinical setting. 
In this study, we investigated which factors are associated 
with the development of ischemic stroke in patients with 
NVAF who are on optimal OAC therapy. We also deter-
mined the etiologic mechanisms of stroke in them. 
MATERIALS AND METHODS
Study population
This study was a multicenter, case-control study with pro-
spective case ascertainment and retrospective data collec-
tion between January 2007 and December 2011. Cases and 
controls were collected from total 14 hospitals in South Ko-
rea. This study was approved by the Institutional Review 
Board at each participating hospital and the requirement for 
informed consent was waived.
Consecutive patients with cerebral infarction or transient 
ischemic attack (TIA) who were admitted to study hospitals 
during study period were investigated for eligibility for this 
study. All patients underwent brain CT/MRI, or both. During 
admission, demographic data, medical history, vascular risk 
factors, and clinical manifestations were collected for each 
patient. Among patients with cerebral infarction or TIA, a pa-
tient was eligible as the cases if they had NVAF with prior 
warfarin therapy and their international normalized ratio 
(INR) was ≥2 at presentation of ischemic stroke or TIA. 
Controls were selected from patients who were treated in 
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followed by multiple arterial territories (9/50, 18.0%), brain-
stem (5/50, 10.0%), and posterior cerebral artery territory 
(1/50, 2.0%). Among 50 cases with cerebral infarction, their 
median National Institutes of Health Stroke Scale (NIHSS) 
score at admission was 3 [interquartile range (IQR) 1‒11].
 
Stroke mechanism and clinical outcomes 
Among 55 patients included in the case group, we could de-
termine the stroke mechanism in 50 patients because 5 pa-
tients had no ischemic lesion on diffusion weighted imag-
ing. Among cases with cerebral infarction (n=50), diffusion 
weighted MRI was performed in 48 patients (96.0%) and an-
giographic studies were done in 49 patients (98.0%). Of 
them, 38 patients (76.0%) were classified as cardioembolic 
stroke and 12 patients (24.0%) as stroke of undetermined eti-
ology due to multiple causes [cardioembolism (CE)+large 
artery atherosclerosis in 9 patients (18.0%) and CE+lacunar 
infarction in 3 patients (6.0%)]. In comparison of baseline 
characteristics between groups according to stroke mecha-
nism, CE was significantly associated with the presence of 
congestive heart failure, while there were no differences in 
the age, gender, risk factors, and previous medication before 
index stroke (Table 1). Neurologic deficits at admission was 
more severe in CE (median NIHSS score at admission 4, 
IQR 2‒15) compared to those in CE+large artery athero-
sclerosis (median 1, IQR 0‒3) or CE+lacunar infarction 
(median 1, IQR 0.5‒1.5) (p=0.022). 
Determinants of ischemic events despite therapeutic 
oral anticoagulation
The comparison between cases and controls is shown in Ta-
ble 2. Cases were more likely to be smokers, and more fre-
quently had a history of previous ischemic stroke or TIA. The 
CHADS2 score or CHA2DS2-VASc score was higher in cases 
than in controls (p<0.001 at each comparison). Other baseline 
characteristics were comparable between two groups. Medi-
an time in therapeutic range in control group was 64.2% 
(IQR 49.2‒81.8%). 
Multivariate analysis showed that smoking and history of 
previous ischemic stroke were independently associated with 
the occurrence of cerebral infarction or TIA (Table 3). Cases 
with CHADS2 score ≥3 or CHA2DS2-VASc score ≥5 had 
significantly higher odds ratio of having cerebral infarction 
or TIA than patients with a CHADS2 score or CHA2DS2-
VASc score of 0‒1 (Table 3). 
The previous ischemic stroke or TIA, which contributed 
two points to the CHADS2/CHA2DS2-VASc score, was a 
the SAS package (version 9.1.3, SAS Inc., Cary, NC, USA). 
Fisher’s exact chi-square test was used for categorical vari-
ables and independent t-test or Kruskal-Wallis test for con-
tinuous variables, as appropriate. In the investigation of de-
terminants for cerebral infarction or TIA on therapeutic 
warfarin treatment between the case and control group, cate-
gorical variables were compared with McNemar test or exact 
McNemar test and continuous variables with paired t-tests or 
Wilcoxon signed-rank test, as appropriate. To find indepen-
dent factors that were associated with development of cere-
bral infarction or TIA while on optimal warfarin therapy, a 
conditional logistic regression analysis was performed using 
variables with p<0.05 on univariate analysis. Statistical sig-
nificance was set at p<0.05. 
RESULTS
 
Characteristics of cases with ischemic stroke 
During the study period, a total of 25415 consecutive patients 
with cerebral infarction or TIA were admitted to study hospi-
tals. Among them, after exclusion of patients without NVAF, 
those without previous OAC therapy, and those whose INR 
was <2, 55 patients (50 patients with cerebral infarction and 
5 patients with TIA) were included in this study as cases 
(Fig. 1). The location of cerebral infarction was most com-
mon in the middle cerebral artery territory (35/50, 70.0%), 
Fig. 1. Patient selection. TIA, transient ischemic attack; NVAF, nonvalvular 
atrial fibrillation; INR, international normalized ratio.
Patients without NVAF (n=21846)
Patients without oral anticoagulation  
therapy (n=2886)
Patients whose INR was <2 (n=628)
55 patients as cases
55 patients as controls 
(matched with cases for 
age and sex)
All ischemic stroke or TIA patients admitted between  
January 2007 and December 2011 (n=25415)
Ischemic stroke or TIA patients with NVAF (n=3569)
Ischemic stroke or TIA patients with known NVAF  
and prior oral anticoagulation (n=683)
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ischemic strokes or TIA were (Table 4). 
DISCUSSION
Despite optimal warfarin treatment, cerebral infarction or 
TIA can occur in patients with NVAF. Among patients with 
NVAF who received warfarin in large contemporary ran-
domized controlled trials, the rate of stroke or non-central 
nervous system embolism was 1.2% to 2.3% per year.13 In 
our study, of 683 ischemic stroke or TIA patients with 
known NVAF and OAC therapy, 8.1% (n=55) had INR 
≥2.0, which is similar to that [7.9% (44/556)] in Fukoka 
Stroke Registry.14 
Occurrence of stroke in patients with NVAF who are on 
warfarin with therapeutic intensity may be ascribed to other 
causes such as atherosclerosis and lacunar infarction. Cere-
bral artery atherosclerosis co-exists in 20‒50% of patients 
with NVAF and may develop stroke.9,15 Likewise, lacunar 
infarction may develop in patients with NVAF.16 However, 
our results demonstrated that most ischemic strokes (76%) 
during OAC developed due to CE.
Considering positive association between risk stratifica-
strong determinant for the cases while CHADS2 score ≥3 
was related with the cases. Therefore, we divided the study 
population into four groups according to the presence of 
previous ischemic stroke or TIA as follows; 1) CHADS2 
score ≤2 but without previous ischemic strokes or TIA (n= 
42); 2) CHADS2 score ≥3 but without previous ischemic 
strokes or TIA (n=29); 3) CHADS2 score 2 and previous 
ischemic strokes or TIA (n=2); 4) CHADS2 score ≥3 and 
previous ischemic strokes or TIA (n=37). Likewise, the 
study population was also divided to four groups according 
to CHA2DS2-VASc score and the previous ischemic strokes 
or TIA; 1) CHA2DS2-VASc score ≤4 but without previous 
ischemic strokes or TIA (n=49); 2) CHA2DS2-VASc score 
≥5 but without previous ischemic strokes or TIA (n=22); 3) 
CHA2DS2-VASc score ≤4 and previous ischemic strokes or 
TIA (n=10); 4) CHA2DS2-VASc score ≥5 and previous isch-
emic strokes or TIA (n=29). After adjusting smoking, the 
CHADS2 score ≥3 with previous ischemic strokes or TIA 
were significantly associated with cases, while the CHADS2 
score ≥3 without previous ischemic strokes or TIA was not. 
Likewise, higher CHA2DS2-VASc scores with previous 
ischemic strokes or TIA were more significantly related with 
cases than higher CHA2DS2-VASc scores without previous 
Table 1. Baseline Characteristics of Cerebral Infarction Cases According to Stroke Mechanisms
CE (n=38) Non-CE (n=12) p value
Age 72.6±7.1 71.2±8.4 0.465
Male sex (%)  22 (57.9)    6 (50.0) 0.631
Permanant atrial fibrillation  27 (71.1)    9 (75.0) 1
Concomitant PCSE    6 (15.8)    2 (16.7) 1
Congestive heart failure  21 (55.3)    1 (8.3) 0.006
Hypertension  34 (89.5)    9 (75.0) 0.337
Diabetes  16 (42.1)    5 (41.7) 0.979
Hyperlipidemia    9 (23.7)    2 (16.7) 1
Smoking  12 (31.6)    5 (41.7) 0.520
Previous ischemic stroke  22 (57.9)    8 (66.7) 0.740
Previous ischemic heart disease    7 (18.4)    3 (25.0) 0.686
Peripheral arterial occlusive diseases    4 (10.5)    1 (8.3) 1
Prior medication
    Antiplatelet  17 (44.7)    6 (50.0) 0.750
    Statin  17 (44.7)    4 (33.3) 0.526
    ACE I  20 (52.6)    8 (66.7) 0.512
    Antiarrhythmic agents  24 (63.2)    5 (41.7) 0.189
International normalized ratio 2.5 (2.2‒3.0) 2.5 (2.2‒2.9) 0.847
NIHSS score, median (IQR)    4 (2‒15)    1 (0‒3) 0.007
Modified Rankin score, median (IQR)    2 (1‒3)    1 (0‒3) 0.098
CE, cardioembolism; PCSE, potential cardiac sources of embolism; ACE I, angiotensin converting enzyme inhibitor; NIHSS, National Institutes of Health 
Stroke Scale; IQR, interquartile range.
Data are presented as mean (standard deviation) or number (percentages). 
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Our findings suggest that warfarin treatment with INR 
2.0‒3.0 may be insufficient to effectively prevent stroke in 
patients with higher CHADS2 score (≥3) or CHA2DS2-VASc 
score (≥5) with a previous stroke or TIA. In these patients, 
more potent antithrombotic measures can be considered. 
Current guidelines mention that it may be reasonable to 
raise the intensity of warfarin to a maximum target INR of 
3.0‒3.5, rather than add an antiplatelet agent in patients with 
AF who sustain ischemic stroke or systemic embolism dur-
ing warfarin treatment with INR 2.0‒3.0.17 However, meta-
analysis showed that new oral anticoagulants (NOACs) 
seemed to be associated with a significant reduction (relative 
tion schemes and prothrombotic conditions, it was expected 
that higher CHADS2 scores or CHA2DS2-VASc scores were 
related with the risk of ischemic stroke or TIA during warfa-
rin treatment. However, even though the CHADS2 score or 
CHA2DS2-VASc score was same, the risk of stroke was sub-
stantially different according to the presence of a history of 
previous stroke or TIA. Although the scores on the risk strat-
ification were similarly high (CHADS2 ≥3 or CHA2DS2-
VASc ≥5), the risk for ischemic stroke was 3.81 times 
(CHADS2 ≥3) and 3 times (CHA2DS2-VASc ≥5) higher in 
patients with a history of previous stroke or TIA than in 
those without history of previous stroke or TIA. 
Table 2. Comparison of Baseline Characteristics between Cases and Controls
Control (n=55) Case (n=55) p value
Age 72.2±7.1 72.2±7.2   1
Male sex 32 (58.2) 32 (58.2)   1
Permanent atrial fibrillation 40 (72.7) 41 (74.5)   1
Concomitant PCSE   6 (10.9)   8 (14.5)   0.774
Congestive heart failure 26 (47.3) 23 (41.8)   0.710
Hypertenstion 40 (72.7) 48 (87.3)   0.077
Diabetes 25 (45.5) 23 (41.8)   0.839
Hyperlipidemia 15 (27.3) 12 (21.8)   0.648
Smoking 3 (5.5) 18 (32.7)   0.001
Previous ischemic stroke 5 (9.1) 34 (61.8) <0.001
Previous ischemic heart disease   6 (10.9) 12 (21.8)   0.210
Peripheral arterial occlusive diseases 1 (1.8)   6 (10.9)   0.125
Prior medication
    Antiplatelet 16 (29.1) 25 (45.5)   0.137
    Statin 20 (36.4) 26 (47.3)   0.345
    ACE I 29 (52.7) 32 (58.2)   0.700
    Antiarrhythmic agents 34 (61.8) 31 (56.4)   0.700
International normalized ratio     2.4 (2.2‒2.7)     2.6 (2.2‒3.1)   0.077
CHADS2 score <0.001
    0 3 (5.5) 1 (1.8)
    1 11 (20.0) 2 (3.6)
    2 19 (34.5)   8 (14.5)
    3 16 (29.1) 24 (43.6)
    4 5 (9.1)   8 (14.5)
    5 1 (1.8) 11 (20.0)
    6 0 (0.0) 1 (1.8)
CHA2DS2-VASc score <0.001
    1 4 (7.3) 2 (3.6)
    2   9 (16.4) 0 (0.0)
    3 11 (20.0) 4 (7.3)
    4 16 (29.1) 13 (23.6)
    5   9 (16.4) 17 (30.9)
    6 5 (9.1)   9 (16.4)
    7 1 (1.8) 10 (18.2)
PCSE, potential cardiac sources of embolism; ACE I, angiotensin converting enzyme inhibitor.
Data are presented as mean (standard deviation) or number (percentages). 
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activation as well as blood stasis in the left atrium.25 Smok-
ing can inhibit secretion of endogenous tissue plasminogen 
activator, increase the plasminogen activator inhibitor-1 ac-
tivity, induce systemic inflammation, activate platelets, and 
damage endothelial cells, which may subsequently lead to a 
hypercoagulable state.26,27 Smoking is a modifiable risk fac-
tor.28 Our results suggest that cessation of smoking is essen-
tial to further reduce stroke risks in patients with NVAF 
who are treated with OAC. 
There are some limitations of our study. Although this 
study was a multicenter case-control study, the data were 
collected retrospectively. Second, we could not investigate 
the effect of age and gender due to the study design that 
matched age and gender between cases and controls. Third, 
because this study was a retrospective cross-sectional de-
sign, our results cannot prove a causal relationship between 
high CHADS2/CHA2DS2-VASc scores and a previous isch-
risk reduction 14%) in rates of stroke or systemic embolism 
in patients with previous stroke or TIA, compared to warfa-
rin treatment.18 Because stroke rate during OAC was re-
ported to be higher in Asians than non-Asians and NOAC 
seems to be more effective than warfarin in Asians than 
non-Asians,19,20 NOAC may have some advantage of treat-
ing this specific group. Recently, local therapy of left atrial 
appendage closure with Watchman device showed some 
potential as alternatives of OAC.21 New trials targeting this 
particular group of patients would be necessary to deter-
mine which treatment strategy is beneficial in them.
In this study, smoking was independently associated with 
the risk of cerebral infarction or TIA. However, previous 
studies have not consistently shown positive relationship 
between smoking and the risks of stroke in patients with 
NVAF.22-24 Intracardiac thrombus formation in NVAF is af-
fected by endocardial damage, inflammation, and platelet 
Table 3. Conditional Logistic Regression Analysis for Ischemic Strokes and TIA 
Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Smoking 6.349 (1.152‒34.997)   0.034   8.477 (1.472‒48.833) 0.017 10.467 (1.248‒87.817) 0.030
Previous ischemic stroke 7.198 (2.393‒21.650) <0.001 - -
CHADS2 score
    0‒1 - 1 -
    2 - 1.650 (0.289‒9.434) 0.573 -
    3 - 12.677 (1.731‒92.832) 0.012 -
    4 -   7.947 (1.102‒57.301) 0.040 -
    ≥5 -   53.434 (3.482‒820.101) 0.004 -
CHA2DS2-VASc score
    0‒1 - - 1
    2 - - NA 0.972
    3 - - 5.692 (0.223‒145.442) 0.293
    4 - - 7.749 (0.438‒137.126) 0.163
    ≥5 - - 46.232 (2.069‒1033.111) 0.016
NA, not applicable; CI, confidence interval; TIA, transient ischemic attack. 
Table 4. Conditional Logistic Regression Analysis According to the Presence of Previous Strokes or TIA
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Smoking   8.084 (1.195‒54.709) 0.032   8.329 (1.069‒64.905) 0.043
According to CHADS2 score component
    0‒2 without previous ischemic stroke 1 -
    ≥3 without previous ischemic stroke   3.853 (0.857‒17.323) 0.079 -
    2 with previous ischemic stroke     3.832 (0.116‒126.306) 0.451 -
    ≥3 with previous ischemic stroke 14.682 (3.492‒61.723) <0.001 -
According to CHA2DS2-VASc score component
    0‒4 without previous ischemic stroke - 1
    ≥5 without previous ischemic stroke -   9.336 (1.412‒61.741) 0.020
    2‒4 with previous ischemic stroke - 12.193 (1.563‒95.139) 0.017
    ≥5 with previous ischemic stroke -   27.914 (4.138‒188.304) 0.001
TIA, transient ischemic attack; CI, confidence interval.
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Nonvitamin-K-antagonist oral anticoagulants in patients with atri-
al fibrillation and previous stroke or transient ischemic attack: a 
systematic review and meta-analysis of randomized controlled tri-
als. Stroke 2012;43:3298-304. 
19. Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen 
TB, Lip GY. Risk of stroke or systemic embolism in atrial fibrilla-
tion patients treated with warfarin: a systematic review and meta-
analysis. Stroke 2013;44:1329-36.
20. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrilla-
tion: an Asian perspective. Thromb Haemost 2014;111:789-97.
21. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber 
K, et al. Percutaneous left atrial appendage closure for stroke pro-
phylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of 
the PROTECT AF (Watchman Left Atrial Appendage System for 
Embolic Protection in Patients with Atrial Fibrillation) Trial. Cir-
culation 2013;127:720-9. 
emic stroke or smoking and stroke risk. Moreover, the con-
trol group was selected if patients had no stroke before 1 
year during OAC, and the sample size of our study was 
small and there is a potential for selection bias, hence the 
results cannot be generalized.
For calculation of CHADS2 scores and CHA2DS2-VASc 
scores, 2 points are given to NVAF patients with a history of 
stroke TIA, and oral anticoagulation use is recommended in 
them. However, we showed that patients with a stroke TIA 
are at very high risk of recurrent stroke despite warfarin 
treatment as is recommended, particularly if their CHADS2 
scores are ≥3 or CHA2DS2-VASc scores are ≥5. Our find-
ings suggest that some other measures to reduce the risk of 
stroke sould be determined in the future in those specific 
groups of patients.  
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